Dudediligence.

AtaiBeckley Inc

ATAINASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$4,243,227

5 notices · 1,027,737 sh

Oct 2025 to Oct 2026

Reported ·

$1,660,343

6 sales · 0 buys

Oct 2025 to Sep 2026

The two figures cover different periods.

5 of 6 reported sales carry the 10b5-1 box. Together they are 0.10% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Sep 2026N2025DJ2026FMAMJJASO2026-07-07: ROBERT HERSHBERG, Form 1442026-06-26: GERD KOCHENDOERFER, Form 1442026-06-25: KEVIN CRAIG, Form 1442026-04-20: KEVIN JAMES CRAIG, Form 1442026-03-11: Feilding-Mellen Cosmo, Form 1442026-01-02: Feilding-Mellen Cosmo, sold2026-03-20: Craig Kevin James, sold2026-04-20: Craig Kevin James, sold2026-06-25: Craig Kevin James, sold2026-06-26: Kochendoerfer Gerd, sold2026-07-07: HERSHBERG ROBERT, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-07-07ROBERT HERSHBERG, Director$496,000
100,000 shplan 2026-04-07144 ↗
Form 4, 2026-07-09: sold 100,000 at $4.96 Form 4 ↗
2026-06-26GERD KOCHENDOERFER, Chief Operating Officer$229,000
50,000 shplan 2026-03-27144 ↗
Form 4, 2026-06-29: sold 50,000 at $5.00 Form 4 ↗
2026-06-25KEVIN CRAIG, Chief Medical Officer$355,109
85,158 shplan 2025-12-19no Form 4 on file144 ↗
2026-04-20KEVIN JAMES CRAIG, Chief Medical Officer$171,593
42,579 shplan 2025-12-19144 ↗
Form 4, 2026-04-22: sold 42,579 at $5.00 Form 4 ↗
2026-03-11Feilding-Mellen Cosmo, Director$2,991,525
750,000 shno plan dateno Form 4 on file144 ↗